According to the firm, even if CAMZYOS were to have similar ECHO monitoring requirements as aficamten, Cytokinetics' drug, the REMS programs for both treatments would likely remain substantially ...

That is slightly better than was achieved by Camzyos (mavacamten) in its phase 3 programme, with the usual caveat about trying to compare studies with different protocols, and it is worth noting ...

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the company's ...

Camzyos (mavacamten), a first-in-class heart disease drug, was approved by the FDA on April 28, 2022 to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic condition that causes ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...